|
Deirdre Y. Gillespie, M.D., joined the Company in 2006. From 2001 to 2005 she was President and Chief Executive Officer of Oxxon Therapeutics, a privately held pharmaceutical company developing immunotherapies for chronic infectious diseases and cancer. Previously, Dr. Gillespie was Chief Operating Officer at Vical Inc, a publicly-traded gene delivery company focusing on immunotherapeutics and cancer vaccines. Dr Gillespie was also Executive Vice President and Chief Business Officer at Vical. Prior to joining Vical in 1998, she was Vice President Business Development at 3-Dimensional Pharmaceuticals and held senior positions at DuPont Merck Pharmaceutical Company, in both Europe and the United States, including Vice President, Marketing. Prior to completing five years of clinical practice in London and Oxford, Dr. Gillespie spent five years in clinical development with Sandoz Pharma AG (Novartis) in the UK and Switzerland. Dr. Gillespie received her M.B.A. from the London Business School and her M.D., and B.Sc. from London University. | 